These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 21497990

  • 1. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
    Huang X, Wang S, Lee CK, Yang X, Liu B.
    Cancer Lett; 2011 Aug 01; 307(1):72-79. PubMed ID: 21497990
    [Abstract] [Full Text] [Related]

  • 2. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
    Huang X, Gao L, Wang S, Lee CK, Ordentlich P, Liu B.
    Cancer Res; 2009 Nov 01; 69(21):8403-11. PubMed ID: 19826038
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
    Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, Tan J, Edgerton SM, Thor AD, Lee CK, Liu B.
    Breast Cancer Res; 2013 Nov 01; 15(5):R101. PubMed ID: 24168763
    [Abstract] [Full Text] [Related]

  • 4. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.
    Huang J, Wang S, Lyu H, Cai B, Yang X, Wang J, Liu B.
    Mol Cancer; 2013 Nov 11; 12(1):134. PubMed ID: 24215614
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.
    Lyu H, Yang XH, Edgerton SM, Thor AD, Wu X, He Z, Liu B.
    Oncotarget; 2016 Jan 19; 7(3):2921-35. PubMed ID: 26621843
    [Abstract] [Full Text] [Related]

  • 7. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
    Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD.
    Cell Cycle; 2011 Sep 01; 10(17):2959-66. PubMed ID: 21862872
    [Abstract] [Full Text] [Related]

  • 8. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin.
    Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, Esteva FJ, Liu B.
    Cancer Res; 2010 Feb 01; 70(3):1204-14. PubMed ID: 20103628
    [Abstract] [Full Text] [Related]

  • 9. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS.
    Mol Pharmacol; 2006 Nov 01; 70(5):1534-41. PubMed ID: 16887935
    [Abstract] [Full Text] [Related]

  • 10. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
    Wang S, Huang X, Lee CK, Liu B.
    Oncogene; 2010 Jul 22; 29(29):4225-36. PubMed ID: 20498641
    [Abstract] [Full Text] [Related]

  • 11. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI.
    Breast Cancer Res; 2007 Jul 22; 9(4):R50. PubMed ID: 17686159
    [Abstract] [Full Text] [Related]

  • 12. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.
    Wang S, Huang J, Lyu H, Lee CK, Tan J, Wang J, Liu B.
    Cell Death Dis; 2013 Mar 21; 4(3):e556. PubMed ID: 23519125
    [Abstract] [Full Text] [Related]

  • 13. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.
    Kirouac DC, Du JY, Lahdenranta J, Overland R, Yarar D, Paragas V, Pace E, McDonagh CF, Nielsen UB, Onsum MD.
    Sci Signal; 2013 Aug 13; 6(288):ra68. PubMed ID: 23943608
    [Abstract] [Full Text] [Related]

  • 14. PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough.
    Hynes NE, Dey JH.
    Cancer Cell; 2009 May 05; 15(5):353-5. PubMed ID: 19411062
    [Abstract] [Full Text] [Related]

  • 15. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
    Lee J, Bartholomeusz C, Mansour O, Humphries J, Hortobagyi GN, Ordentlich P, Ueno NT.
    Breast Cancer Res Treat; 2014 Jul 05; 146(2):259-72. PubMed ID: 24916181
    [Abstract] [Full Text] [Related]

  • 16. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B, Citri A, Isola J, Yarden Y, Szöllosi J, Vereb G.
    Immunol Lett; 2006 Apr 15; 104(1-2):146-55. PubMed ID: 16384610
    [Abstract] [Full Text] [Related]

  • 17. Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization.
    Li B, Meng Y, Zheng L, Zhang X, Tong Q, Tan W, Hu S, Li H, Chen Y, Song J, Zhang G, Zhao L, Zhang D, Hou S, Qian W, Guo Y.
    Cancer Res; 2013 Nov 01; 73(21):6471-83. PubMed ID: 24046294
    [Abstract] [Full Text] [Related]

  • 18. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Chan CT, Metz MZ, Kane SE.
    Breast Cancer Res Treat; 2005 May 01; 91(2):187-201. PubMed ID: 15868447
    [Abstract] [Full Text] [Related]

  • 19. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D.
    Cancer Res; 2002 Oct 15; 62(20):5703-10. PubMed ID: 12384528
    [Abstract] [Full Text] [Related]

  • 20. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllosi J, Brockhoff G.
    Exp Cell Res; 2005 Apr 01; 304(2):604-19. PubMed ID: 15748904
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.